title: SGLT2 Inhibitors and Ketoacidosis: Cause for Concern?
authors.affiliation: 1 Division of Endocrinology, University of Texas Medical Branch , Galveston, Texas.
authors.forename: Nicola
authors.initials: N
authors.lastname: Abate
authors.affiliation: 2 Endocrine Clinics, Bayarea Metabolic Health , Houston, Texas.
authors.forename: Manisha
authors.initials: M
authors.lastname: Chandalia
mesh_terms: D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D016883:Diabetic Ketoacidosis / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D019317:Evidence-Based Medicine; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D018570:Risk Assessment; D012307:Risk Factors; D051297:Sodium-Glucose Transporter 2 / Q000378:metabolism; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors